10-Q: Cara Therapeutics Explores Strategic Options After Discontinuing Notalgia Paresthetica Program

Cara Therapeutics is exploring strategic alternatives to maximize shareholder value after discontinuing its notalgia paresthetica clinical program due to lack of efficacy.

Summary

• Cara Therapeutics has announced a streamlined operating plan focused on exploring strategic alternatives after discontinuing its notalgia paresthetica (NP) clinical program.
• The decision to halt the NP program followed disappointing results from a dose-finding study where oral difelikefalin did not show meaningful clinical benefit compared to placebo.
• In connection with this plan, the company has implemented a second workforce reduction of approximately 70% in June 2024.
• The company's lead product, KORSUVA injection, is approved for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis in multiple regions.
• Cara Therapeutics has out-licensed commercialization rights for KORSUVA injection to CSL Vifor (excluding Japan and South Korea) and Maruishi (Japan).
• The company has sold its future royalty and milestone payments for KORSUVA/Kapruvia to HCR, limiting future revenue from these sources.
• As of September 30, 2024, the company had unrestricted cash and cash equivalents and marketable securities of $42.0 million and an accumulated deficit of $747.9 million.
• The company has incurred substantial net losses and negative cash flows from operating activities and expects this trend to continue for the foreseeable future.
• The company is not in compliance with Nasdaq's minimum shareholders equity requirement and has until January 27, 2025 to regain compliance with the minimum bid price requirement.

Sentiment

Score: 3

Explanation: The document reflects a significant setback with the discontinuation of the NP program and the need to explore strategic alternatives. The company's financial position and Nasdaq compliance issues add to the negative sentiment. While there are some positives, such as the commercial product and out-licensing agreements, the overall outlook is uncertain.

Positives

• The company has a commercial product, KORSUVA injection, approved in multiple regions.
• The company has out-licensed commercialization rights for KORSUVA injection to CSL Vifor and Maruishi.
• The company has taken steps to reduce operating expenses through workforce reductions.
• The company has a universal shelf registration statement that provides for aggregate offerings of up to $300 million of common stock, preferred stock, debt securities, warrants or any combination thereof.

Negatives

• The company discontinued its notalgia paresthetica (NP) clinical program due to lack of efficacy.
• The company is not in compliance with Nasdaq's minimum shareholders equity requirement and has until January 27, 2025 to regain compliance with the minimum bid price requirement.
• The company has incurred substantial net losses and negative cash flows from operating activities.
• The company has sold its future royalty and milestone payments for KORSUVA/Kapruvia to HCR, limiting future revenue from these sources.
• The company recorded a $4.3 million impairment charge on its right of use asset as a result of the assignment of its corporate lease in September 2024.
• The company wrote down approximately $1.0 million and $2.5 million of commercial supply inventory due to obsolescence for the three and nine months ended September 30, 2024, respectively.
• The company recorded an expense in other general and administrative expense for $1.4 million for the nine months ended September 30, 2024 as a result of the negative profit share amount in the second quarter of 2024.

Risks

• The company may not be successful in identifying and implementing any potential strategic alternatives in a timely manner or at all.
• The company may fail to regain compliance with Nasdaq listing requirements, leading to delisting.
• The company may be unable to raise additional capital when needed, which would force it to delay, reduce or eliminate product development programs.
• The company may not be able to successfully complete clinical development, obtain regulatory approvals, or commercialize product candidates.
• The company relies on third parties for clinical trials and manufacturing, which may not perform satisfactorily.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company may experience delays or difficulties in the enrollment of patients in clinical trials.
• The company may be subject to product liability lawsuits.
• The company may be subject to cybersecurity breaches, loss or leakage of data or other disruptions.
• The company may be subject to claims that its employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• The company may be involved in lawsuits to protect or enforce its patents or the patents of its licensors, which could be expensive, time consuming and may ultimately be unsuccessful.
• The company may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
• The company may be subject to stringent and evolving U.S. and foreign laws, regulations and standards, contracts, industry standards, policies and other obligations related to data privacy and security.
• The company may be subject to recent legislation, regulatory proposals and healthcare payer initiatives that may increase its costs of compliance and adversely affect its ability to market its products, obtain collaborators and raise capital.
• The company's employees, independent contractors, consultants, and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
• The company's business involves the use of hazardous materials and it and its third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how it does business.

Future Outlook

The company expects that its current unrestricted cash and cash equivalents and marketable securities will be sufficient to fund its currently anticipated operating plan for at least the next 12 months. The company is exploring strategic alternatives to maximize shareholder value.

Management Comments

• The Board of Directors approved a streamlined operating plan exploring strategic alternatives focused on maximizing shareholder value.
• The company's decision to discontinue the clinical program in NP followed the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with NP in which oral difelikefalin did not demonstrate a meaningful clinical benefit at any dose compared to placebo.
• The company intends to continue to actively monitor the bid price for its common stock between now and January 27, 2025, and will consider available options to resolve the deficiency and regain compliance with the Rule.

Industry Context

The announcement reflects the challenges and risks inherent in pharmaceutical development, particularly in the competitive landscape of pruritus treatments. The company's decision to discontinue the NP program highlights the importance of clinical trial results in shaping strategic direction. The company's focus on strategic alternatives is a common response to such setbacks, aiming to maximize value for shareholders.

Comparison to Industry Standards

• The discontinuation of the NP program due to lack of efficacy is not uncommon in the pharmaceutical industry, where clinical trial failures are a regular occurrence.
• The company's decision to explore strategic alternatives is a typical response to such setbacks, similar to other companies facing clinical trial failures.
• The company's reliance on third-party manufacturers and CROs is standard practice in the industry, but also introduces risks related to performance and compliance.
• The company's financial position, with a significant accumulated deficit and reliance on external funding, is typical for a development-stage biopharmaceutical company.
• The company's challenges in maintaining Nasdaq listing compliance are not unique, as many small-cap biotech companies face similar pressures.

Corporate Governance

Related Party Transactions

• As of September 30, 2024, Vifor International owned 7,396,770, or 13.5%, of the Company's common stock.
• CSL Vifor and its affiliates are considered related parties as of September 30, 2024 and December 31, 2023.
• Amounts due from CSL Vifor of $435,000 and $2,765,000, respectively, primarily relating to royalty payments from CSL Vifor in the current period and the Company's share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor, its commercial supply of KORSUVA injection to CSL Vifor, and royalty payments from CSL Vifor in the prior period were included within accounts receivable, net related party.
• The Company's collaborative revenue of $1,298,000 and $1,932,000 from its share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor was included within collaborative revenue for the three months ended September 30, 2024 and 2023, respectively.
• The Company's collaborative revenue of $2,086,000 and $10,092,000 from its share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor was included within collaborative revenue for the nine months ended September 30, 2024 and 2023, respectively.
• Sales of KORSUVA injection to CSL Vifor of $640,000 and $5,843,000 were included within commercial supply revenue for the nine months ended September 30, 2024 and 2023, respectively.
• Sales of KORSUVA injection to CSL Vifor of $1,252,000 were included within commercial supply revenue for the three months ended September 30, 2023.
• The Company recorded $167,000 and $415,000 as royalty revenue based on net sales of Kapruvia outside of the United States during the three and nine months ended September 30, 2023, respectively.
• The Company recorded $435,000 and $1,084,000 as other revenue from its royalty payments from CSL Vifor for the three and nine months ended September 30, 2024, respectively.

Stakeholder Impact

• Shareholders face uncertainty due to the strategic review process and potential delisting from Nasdaq.
• Employees have been impacted by workforce reductions.
• Customers may experience changes in product availability or support.
• Suppliers and creditors may face uncertainty due to the company's financial situation.
• Collaborators may be affected by changes in the company's strategic direction.

Next Steps

• The company will continue to explore strategic alternatives to maximize shareholder value.
• The company will actively monitor the bid price of its common stock and consider options to regain compliance with Nasdaq listing requirements.
• The company will continue to assess its available options to regain compliance with the Shareholders Equity Requirement.

Key Dates

Keywords

pruritus, difelikefalin, KORSUVA, Kapruvia, clinical trials, strategic alternatives, Nasdaq, biopharmaceutical, CKD, hemodialysis